Guardion Health Sciences Announces Development of New Vision/Energy Support Drink – EPIQ-V
December 16 2020 - 8:00AM
Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the
“Company”), a specialty health sciences company that develops
clinically supported nutrition, medical foods and medical devices,
with a focus in the ocular health marketplace, announced progress
on the introduction of its new vision support/energy drink, Epiq-V,
which is under development for the United States and international
markets.
Epiq-V contains Lutein, a primary ingredient in
the Company’s flagship product, Lumega-Z, and is being developed
for an adult market as a vision health and support product
concurrently with a second formulation for introduction as a visual
attention and energy drink primarily focused on the youth market to
support video gaming and other close-up device viewing requirements
for this age group. The initial round of testing has been completed
and the final round is currently underway and expected to be
completed by the end of the first quarter of 2021. The
commercial product is expected to be available 12 to 16 weeks after
the final round of testing. With respect to the Asian market,
specifically China, the Company has already filed and been granted
a trademark (utilizing Chinese characters) for the Epiq-V brand
name. Trademark protection for the brand has also been submitted
for approval in the United States.
David Evans, Ph.D., Guardion’s interim President
and Chief Executive Officer, and Chief Science Officer, stated, “We
have long emphasized the importance of using our unique formulation
capabilities to access markets both in the United States and
internationally, and during 2020 we established a presence in Asia.
With the development and eventual distribution of Epiq-V, we hope
to expand our presence in Asia by providing a product line that is
designed to support overall ocular health and attention.”
Dr. Evans concluded, “We are very proud of our
approach to product development, which includes the integration of
research-driven science combined with the development of innovative
products that appeal to a wide range of demographics. We look
forward to providing further updates on Epiq-V and other products
as warranted.”
About Guardion Health
Sciences
Guardion is a specialty health sciences company
that develops clinically supported nutrition, medical foods and
medical devices, with a focus in the ocular health marketplace.
Located in San Diego, California, the Company combines targeted
nutrition with innovative, evidence-based diagnostic technology.
Guardion boasts impressive Scientific and Medical Advisory Boards.
Information and risk factors with respect to Guardion and its
business, including its ability to successfully develop and
commercialize its proprietary products and technologies, may be
obtained in the Company’s filings with the SEC at www.sec.gov.
Forward-Looking Statement
Disclaimer
With the exception of the historical information
contained in this news release, the matters described herein may
contain forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. Statements
preceded by, followed by or that otherwise include the words
“believes,” “expects,” “anticipates,” “intends,” “projects,”
“estimates,” “plans” and similar expressions or future or
conditional verbs such as “will,” “should,” “would,” “may” and
“could” are generally forward- looking in nature and not historical
facts, although not all forward-looking statements include the
foregoing. These statements involve unknown risks and uncertainties
that may individually or materially impact the matters discussed
herein for a variety of reasons that are outside the control of the
Company, including, but not limited to, the Company’s ability to
raise sufficient financing to implement its business plan, the
impact of the COVID-19 pandemic on the Company’s business,
operations and the economy in general, and the Company’s ability to
successfully develop and commercialize its proprietary products and
technologies. Readers are cautioned not to place undue reliance on
these forward- looking statements, as actual results could differ
materially from those described in the forward-looking statements
contained herein. Readers are urged to read the risk factors set
forth in the Company’s filings with the SEC, which are available at
the SEC’s website (www.sec.gov). The Company disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Investor Relations Contact:CORE IRScott
Arnold516-222-2560scotta@coreir.com
Media Relations Contact:Jules AbrahamDirector
of Public RelationsCORE IR917-885-7378julesa@coreir.com
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Sep 2023 to Sep 2024